- News & Events
- Contact Us
Amgen Appoints Beth Seidenberg as Senior Vice President -- DevelopmentTHOUSAND OAKS, Calif., Jan 10, 2002 (BUSINESS WIRE) -- Amgen (Nasdaq:AMGN) announced today that Beth C. Seidenberg, M.D. has been named Senior Vice President, Development effective January 14, 2002. Dr. Seidenberg will report to Roger M. Perlmutter, M.D., Ph.D., Executive Vice President -- Research and Development. She will also serve on the company's executive committee.
Dr. Seidenberg comes to Amgen from the Bristol-Myers Squibb Pharmaceutical Research Institute (BMS), which she joined in 2000. She served as Senior Vice President for Global Development. At Bristol she led a 1,500-person organization with full responsibility for the clinical development of new drug candidates.
"We are extremely pleased that Beth Seidenberg, a globally recognized expert in immunology and inflammation, has decided to join the Amgen team. Beth has demonstrated her talent in moving drug candidates with speed and care through the development process, both at Merck and Bristol-Myers Squibb. She is a real leader in clinical research," said Dr. Perlmutter.
Prior to joining BMS, she rose quickly during 11 years at the Merck Research Laboratories to Vice President, with special responsibility in pulmonary medicine and inflammation. She was also part of the Merck team that evaluated in-licensing opportunities.
A graduate of Barnard College and the University of Miami School of Medicine and thereafter completed her medical residency at Johns Hopkins and the George Washington University; from 1987 to 1989 Dr. Seidenberg pursued research at National Institute of Allergy & Infectious Diseases focusing on pulmonary and immunology research. She is board certified in pediatrics and also in immunology and allergy.
Dr. Seidenberg's career milestones include the approval and launch of SINGLAIR(R) for treatment of asthma in adults and children, and the development and approval of VIOXX(R) for pain management. She is credited with decisive, effective leadership in bringing both these products to successful approval.
At Amgen she will be responsible for worldwide Clinical Development including Clinical Operations and Regulatory Affairs.
Amgen is a global biotechnology company that discovers, develops, manufactures and markets cost-effective human therapeutics based on advances in cellular and molecular biology.
EDITORS NOTE: An electronic version of this news release may be accessed via our web site at www.Amgen.com. Visit the Corporate Center and click on Amgen News. Journalists and media representatives may sign up to receive all news releases electronically at time of announcement by filling out a short form in the Amgen News section of the web site.
CONTACT: Amgen, Thousand Oaks
Jeff Richardson, 805/447-3227 (media)
Cary Rosansky, 805/447-4634 (investors)